Wednesday, May 19, 2021 2:06:30 PM
The Dr. Jay Lalezari interview that was recently posted on the board was excellent. Such a compassionate and honorable man, I have great respect for his integrity.
If you do nothing else, you owe it to yourself (and your investment) to listen to this 5-minute excerpt from that interview:
http://lalezari.s3.amazonaws.com/lalezari.mp3
In 5 short minutes, we learn the following:
1. There is an unproductive relationship between the FDA and CytoDyn
2. That unproductive relationship was forged over many years during the HIV trials
3. Everything in CytoDyn’s development of the HIV indication was “ass-backwards”
4. CytoDyn has stumbled along for years, enrolled hundreds of patients, and spent untold millions of dollars
5. In the course of those years, the relationship with the FDA became unproductive
6. The way that CytoDyn does business is completely foreign to the FDA
7. The FDA frowns upon Nader’s frequent press releases, which are sometimes issued two-a-day
8. The FDA looks at that behavior as being “out of bounds” as a way of running a company
9. There is a personal history between the FDA and CytoDyn which is troublesome
10. The FDA doesn’t like the “press release way” of running the company
11. The dysfunctional relationship between the FDA and CytoDyn has gone “nowhere”
My Conclusions:
- The FDA is going to continue stringing CytoDyn along, and likely has no intention of approving the Combo HIV BLA because of the damaged relationship with Nader.
- In the face of a terrible pandemic, and with a therapy that shows great promise and “does no harm”, the FDA has likely not granted leronlimab an EUA because they do not respect or trust Nader, or way he runs the business.
- It is now clear why the FDA released that damaging letter a couple of days ago, and why they did it during market hours – they did it to publicly spank Nader
- Every other leronlimab indication on the roadmap, COVID, LONG COVID, HIV, CANCER, NASH, GvHD, MS, STROKE and all of the others, will likely experience an insurmountable uphill battle because of Nader’s troublesome relationship with the FDA.
- Our many conspiracy theories about Big Pharma influence being used to hurt CytoDyn are likely misplaced – it is the FDA having no respect for Nader and CytoDyn
- It is now finally clear why Nader has been so obsequious towards the FDA – he has damaged that relationship and he is desperately trying to prevent it from getting worse -- and in the process he has destroyed leronlimab’s chances of saving lives and treating terrible diseases.
Dr. Jay Lalezari is one of the most honest and sincere men I have ever come across. I implicitly trust what has has said in this interview.
At the same time, I have great respect for what Nader has accomplished, and I recognize that we wouldn’t be here without him.
However, the millions of sick and dying patients that can be helped by leronlimab deserve better -- and we as investors deserve better.
Nader’s said it himself yesterday – if he is doing a bad job – he needs to leave.
Nader's terminally damaged relationship with the FDA has effectively 'shelved' leronlimab and I see no forward progress while he is at the helm.
Lastly, if you want to listen to the full interview, it is available using this link:
https://savageminds.substack.com/p/jay-lalezari
Recent CYDY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:48:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:47:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:47:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:46:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:45:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:45:06 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/17/2024 09:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/15/2024 09:16:35 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/11/2024 01:00:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/01/2024 09:15:42 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 09/30/2024 09:01:16 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:06 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/07/2024 12:44:56 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/07/2024 12:42:22 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM